134 related articles for article (PubMed ID: 27211090)
41. Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging.
Watcharin W; Schmithals C; Pleli T; Köberle V; Korkusuz H; Huebner F; Zeuzem S; Korf HW; Vogl TJ; Rittmeyer C; Terfort A; Piiper A; Gelperina S; Kreuter J
Eur J Pharm Biopharm; 2014 May; 87(1):132-41. PubMed ID: 24365328
[TBL] [Abstract][Full Text] [Related]
42. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.
Ahn SS; Kim MJ; Lim JS; Hong HS; Chung YE; Choi JY
Radiology; 2010 May; 255(2):459-66. PubMed ID: 20413759
[TBL] [Abstract][Full Text] [Related]
43. Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver.
Khan AS; Hussain HK; Johnson TD; Weadock WJ; Pelletier SJ; Marrero JA
J Magn Reson Imaging; 2010 Aug; 32(2):360-6. PubMed ID: 20677263
[TBL] [Abstract][Full Text] [Related]
44. [Double-contrast MR Imaging for Hepatocellular Carcinoma].
Han JK; Kim SH
Korean J Hepatol; 2006 Jun; 12(2):247-50. PubMed ID: 16804351
[No Abstract] [Full Text] [Related]
45. Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer.
Liu Y; Chen Z; Liu C; Yu D; Lu Z; Zhang N
Biomaterials; 2011 Aug; 32(22):5167-76. PubMed ID: 21521627
[TBL] [Abstract][Full Text] [Related]
46. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma.
Numata K; Fukuda H; Miwa H; Ishii T; Moriya S; Kondo M; Nozaki A; Morimoto M; Okada M; Takebayashi S; Maeda S; Nozawa A; Nakano M; Tanaka K
Eur J Radiol; 2014 Jan; 83(1):95-102. PubMed ID: 24176532
[TBL] [Abstract][Full Text] [Related]
47. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis.
Ward J; Guthrie JA; Scott DJ; Atchley J; Wilson D; Davies MH; Wyatt JI; Robinson PJ
Radiology; 2000 Jul; 216(1):154-62. PubMed ID: 10887242
[TBL] [Abstract][Full Text] [Related]
48. MR imaging of hepatocellular carcinoma.
Onaya H; Itai Y
Magn Reson Imaging Clin N Am; 2000 Nov; 8(4):757-68. PubMed ID: 11149678
[TBL] [Abstract][Full Text] [Related]
49. Hepatocellular carcinoma with indeterminate or false-negative findings at initial MR imaging: effect on eligibility for curative treatment initial observations.
Choi D; Mitchell DG; Verma SK; Bergin D; Navarro VJ; Malliah AB; McGowan C; Hann HW; Herrine SK
Radiology; 2007 Sep; 244(3):776-83. PubMed ID: 17690322
[TBL] [Abstract][Full Text] [Related]
50. Correction to The Dixon technique and the frequency-selective fat suppression technique in three-dimensional T1 weighted MRI of the liver: a comparison of contrast-to-noise ratios of hepatocellular carcinomas-to-liver.
Br J Radiol; 2016 Oct; 89(1066):20150117e. PubMed ID: 27572243
[No Abstract] [Full Text] [Related]
51. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data.
Bonekamp S; Jolepalem P; Lazo M; Gulsun MA; Kiraly AP; Kamel IR
Radiology; 2011 Sep; 260(3):752-61. PubMed ID: 21771960
[TBL] [Abstract][Full Text] [Related]
52. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI).
Motosugi U; Ichikawa T; Sou H; Sano K; Ichikawa S; Tominaga L; Araki T
J Magn Reson Imaging; 2009 Oct; 30(4):849-54. PubMed ID: 19787734
[TBL] [Abstract][Full Text] [Related]
53. [Advances in imaging modalities of hepatocellular carcinoma].
Imai Y; Kogita S; Igura T; Sawai Y; Ohama H; Fukuda K; Seki Y; Takamura M; Okada M; Murakami T
Nihon Shokakibyo Gakkai Zasshi; 2011 Jun; 108(6):916-27. PubMed ID: 21646759
[No Abstract] [Full Text] [Related]
54. Proper definitions of MRI contrast enhancement in liver tumors.
Ni Y; Chen F; Wang H; Feng Y; Li J; Jiang Y
J Gastroenterol; 2010 Mar; 45(3):349-50; author reply 351-2. PubMed ID: 20012916
[No Abstract] [Full Text] [Related]
55. Hepatocellular carcinoma: contrast-enhanced MRI.
Yu JS; Kim MJ
Abdom Imaging; 2002; 27(2):157-67. PubMed ID: 11847575
[No Abstract] [Full Text] [Related]
56. Management of Small Hepatocellular Carcinoma.
Civan JM
Radiology; 2016 May; 279(2):651-2. PubMed ID: 27089193
[No Abstract] [Full Text] [Related]
57. Evaluation of liver diseases via MTC and contrast agent.
Chen JH; Yeung HN; Lee SK; Chai JW
J Magn Reson Imaging; 1999 Feb; 9(2):257-65. PubMed ID: 10077022
[TBL] [Abstract][Full Text] [Related]
58. Response.
Rosenkrantz AB; Kang SK; Kierans AS
Radiology; 2016 May; 279(2):652. PubMed ID: 27556126
[No Abstract] [Full Text] [Related]
59. Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?
Kim SY
Clin Mol Hepatol; 2020 Jul; 26(3):309-311. PubMed ID: 32536046
[No Abstract] [Full Text] [Related]
60. Hepatocellular carcinoma and precancerous lesions: advances in imaging.
Choi BI
Abdom Imaging; 2002; 27(2):115-6. PubMed ID: 11847570
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
